3 results
4295 The Impact of Social Determinants of Health on Hepatocellular Carcinoma Outcomes
- Lauren Devore Nephew, Susan Rawl, Archita Desai, Eric Orman, Marwan Ghabril, Kavish Patidar, Naga Chalasani
-
- Journal:
- Journal of Clinical and Translational Science / Volume 4 / Issue s1 / June 2020
- Published online by Cambridge University Press:
- 29 July 2020, pp. 89-90
-
- Article
-
- You have access Access
- Open access
- Export citation
-
OBJECTIVES/GOALS: Achieving therapy for hepatocellular carcinoma (HCC) involves navigating through a complex cascade of care. Non-HCC cancer mortality has been associated with social determinants of health outside of cancer specific risk. Our objective is to explore the impact of social determinants on HCC outcomes. METHODS/STUDY POPULATION: Patients with HCC were enrolled from 3 hospitals form June, 1 2019 to December 1, 2019. A chart review was done to collect information on liver disease severity and cancer stage. Patients were interviewed to collect information on the following: 1) socioeconomic status (income, education, insurance status, and employment status), 2) literacy (Rapid Estimate of Adult Literacy in Medicine (REALM-R) and Brief Health Literacy Screening Tool (BREIF)), 3) social support (Patent Reported Outcome Measurement Information System (PROMIS) instrumental and information support tool), 4) quality of life (PROMIS global and mental health tool), 5) substance abuse, and 6) linkage to care. RESULTS/ANTICIPATED RESULTS: Data compiled on the social determinants of health revealed (n = 35): 1) 60.0% of patients had incomes below $30,000 per year, 60.0% of patients had not gone past high school for education, and 8.6% had full time employment, 2) the average BREIF score was 10.3 (range 3-15)(4-12 indicate limited literacy). The average REALM-R score was 5.5 (range 0-8) (<6 indicate at risk for poor literacy), 3) patients had strong instrumental (T score 61.4±7.1) and information social support (T score 64.6±4.7) (mean T scores calibrated to a general population mean of 50), 4) patients had poor mental (T score 43.7 ±6.5) and physical quality of life (T score 46.6 ±9.9), 5) 25.7% of patients reported alcohol use in the past 90 days 6) 80.0% of patients reported that their doctor had spoken to them about liver transplantation. DISCUSSION/SIGNIFICANCE OF IMPACT: This patient population was well linked to care with good social support. However their literacy, socioeconomic status, mental and global health was poor and substance use history complex. Continued follow up of this cohort is planned to determine how these factors might impact their ability to navigate through the care cascade as well as survival.
3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes
- Lauren Devore Nephew, Susan Rawl, Naga Chalasani
-
- Journal:
- Journal of Clinical and Translational Science / Volume 3 / Issue s1 / March 2019
- Published online by Cambridge University Press:
- 26 March 2019, p. 99
-
- Article
-
- You have access Access
- Open access
- Export citation
-
OBJECTIVES/SPECIFIC AIMS: Black patients with hepatocellular carcinoma (HCC) receive fewer curative therapies and have higher mortality than other groups. Reducing this disparity will require an in-depth understanding of patient comorbidities, tumor characteristics, and social determinants of health. Our objectives are to a) perform a multi-center retrospective cohort study of black and white patients diagnosed with HCC in the Indianapolis area. b) prospectively enroll black and white patients with HCC to collect clinical characteristics as well as data on the social determinants of health. METHODS/STUDY POPULATION: A retrospective chart review of patients with a diagnosis of HCC from 2010-2017 from five area Indianapolis hospitals will be performed. Demographics, comorbidities, liver disease severity, and tumor characteristics will be collected using the Indiana Network for Patient Care database and compared between black and white patients. Concomitantly, a prospective cohort of black and white patients will be enrolled and surveyed to collect data on socioeconomic status and income adequacy, literacy, functional status, substance abuse history, social support, activation, and adherence. The primary outcomes are the receipt of curative therapies for HCC including liver transplantation, resection or ablation. The secondary outcome is mortality. Multivariable logistic regression models will be used to explore disparities seen in the primary and secondary outcomes. RESULTS/ANTICIPATED RESULTS: These preliminary results include Indiana University Hospital (IUH) findings; a multicenter analysis is underway. The IUH cohort included 1,032 (86%) white and 164 (14%) black patients. Black and white patients had similar Model for End-Stage Liver Disease and Child-Pugh scores. There was a trend toward larger tumor size (5.3 cm vs. 4.7 cm; P = 0.05) in black patients; however, Barcelona Clinic Liver Cancer staging and Milan criteria were similar. Black patients were less likely to undergo liver transplantation than white patients—a disparity that was not attenuated (odds ratio [OR], 0.43; 95% confidence interval [CI]: 0.21-0.90) on multivariable analysis. Substance abuse was more frequently cited as the reason black patients within Milan criteria failed to undergo transplantation than white patients. Survival was similar between the two groups. DISCUSSION/SIGNIFICANCE OF IMPACT: Racial differences in patient and tumor characteristics were small in our single center analysis and did not explain the disparity in liver transplantation. This analysis however only reflects 25% of patients diagnosed with HCC in the Indianapolis metropolitan, highlighting the need for a multicenter study. Higher rates of substance abuse in black patients within Milan criteria who failed to undergo transplantation suggest social factors contribute to this disparity and highlight the need for a prospective study that can explore these and other social factors.
11 - Drug-Induced Liver Disease (DILI)
- Edited by Zobair M. Younossi
-
- Book:
- Practical Management of Liver Diseases
- Published online:
- 08 August 2009
- Print publication:
- 16 June 2008, pp 174-194
-
- Chapter
- Export citation
-
Summary
BACKGROUND
Hepatotoxicity is among the most common and feared adverse drug reactions. Television commercials advertising pharmaceuticals warn patients to beware of taking various medications if they have liver disease. Lawyers publicly recruit business from patients or loved ones of patients who may have had a hepatotoxic drug reaction; there were several newspaper ads placed by law firms after troglitazone was removed from the market, for example. Clinicians are wary of prescribing medications described to have potential adverse effects on the liver without frequent monitoring of liver tests or referral to a hepatologist. In fact, hepatotoxicity is the most common single adverse drug reaction leading to drug withdrawal and refusal for FDA approval. For hepatologists and primary care physicians alike, drug hepatotoxicity is a tough clinical problem because it is a diagnosis of exclusion, may be difficult to diagnose, and there is no clear treatment other than drug withdrawal in many cases. From a public health standpoint, the difficulty in studying and predicting hepatotoxic drug reactions in a few patients may prevent thousands from receiving medications that would be beneficial to them. In short, drug-induced liver injury (DILI) is a complicated and often confusing entity that can pose problems for patients and the practitioners who care for them. In this article, we will provide an overview of idiosyncratic DILI with relatively minor focus on acetaminophen hepatotoxicity.
EPIDEMIOLOGY
The true incidence of idiosyncratic DILI is unknown. The difficulty of correctly establishing the diagnosis as well as underreporting to regulatory agencies makes determining disease frequency problematic.